ADORA2B

Across TCGA pan-cancer cohorts, ADORA2B RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ADORA2B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ADORA2B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ADORA2B is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

KIRC, HNSC, and BRCA are the cancer types where ADORA2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADORA2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	+0.666	<.001	10	view →
HNSC	Male	All	+1.308	<.001	8	view →
BRCA	All	III,IV	−0.857	<.001	8	view →
LUAD	Female	All	+0.792	<.001	6	view →
CHOL	All	All	+2.384	<.001	5	view →
KICH	Female	All	−1.043	.001	4	view →
LUSC	All	II,III,IV	+0.950	<.001	4	view →
STAD	Male	All	+0.899	.017	3	view →
PAAD	All	All	+2.239	.041	2	view →
ESCA	Male	All	+1.650	.032	2	view →
KIRP	All	II,III,IV	+0.668	.028	2	view →
PRAD	All	All	−0.576	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ADORA2B–KIRC

Open the KIRC breakdown →